Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Roy S. Herbst's publication output changed over time?
ScholarIQpublication output · 2014–2015
Output grew0% over the shown period — from 1 works in 2014 to 1 in 2015.
1
1
20142015
What are the most-cited papers on Roy S. Herbst?
ScholarIQmost cited works
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst, Paul Baas, Dong‐Wan Kim, Enriqueta Felip, José Luis Perez‐Gracia, Ji‐Youn Han, Julian R. Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung‐Ju Ahn, Margarita Majem, Mary J. Fidler, Gilberto de Castro, Marcelo Garrido, Gregory M. Lubiniecki, Yue Shentu, Ellie Im, Marisa Dolled‐Filhart, Edward B. Garon
The Lancet. 20156,550 Citations
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst, Jean‐Charles Soria, Marcin Kowanetz, Gregg Fine, Omid Hamid, Michael S. Gordon, Jeffery A. Sosman, David F. McDermott, John D. Powderly, Scott Gettinger, Holbrook E. Kohrt, Leora Horn, Donald P. Lawrence, Sandra Rost, Maya K. Leabman, Yuanyuan Xiao, Ahmad Mokatrin, Hartmut Koeppen, Priti S. Hegde, Ira Mellman, Daniel S. Chen, F. Stephen Hodi
Nature. 20145,287 Citations
Related on ScholarIQ
Yale Cancer Center
University
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Paper
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Paper
Cancer Immunotherapy and Biomarkers
Topic
Cancer Genomics and Diagnostics
Topic
Lung Cancer Treatments and Mutations
Topic